ResMed Price Target Raised to $270.00/Share From $240.00 by Citigroup

What happened

Citigroup raised its price target for ResMed shares to $270.00 from $240.00 per share while keeping a Neutral rating on the stock, according to a Benzinga ratings update.

Confirmed

Global impact / market context

A higher price target means Citigroup expects ResMed shares to be worth more than it previously estimated, which can shape how investors view the stock. Keeping a Neutral rating signals the analyst sees limited reason to buy aggressively despite the raised target.

Analyst inference

Analyst price target changes often draw investor attention because they reflect updated views on a company's value. For ResMed, the raised target suggests improved expectations, but the unchanged Neutral rating indicates the analyst is not recommending a strong buy.

Analyst inference

What to watch

1. Citigroup maintained a Neutral rating on ResMed while raising the price target to $270.00 from $240.00 per share, per the Benzinga ratings update. Confirmed
2. Watch whether other analysts change their own ResMed price targets or ratings, since moves by one brokerage can influence how investors position themselves in the stock. Analyst inference
3. Watch ResMed's future financial results and guidance, because analyst targets often shift when company earnings, revenue, or spending plans differ from expectations. Analyst inference

Evidence

• Original source link unavailable